Pavblu (aflibercept-ayyh) NDC 55513-056 · J-Code J0178

NDC codes

FDA NDC Directory

Product NDC (as listed)55513-056Labeler and product segments. Claims need a package NDC.

Product NDC at billing width55513-0056Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
55513-056-01	55513005601	1 SYRINGE in 1 CARTON (55513-056-01) / .05 mL in 1 SYRINGEMarketed from Oct 28, 2024
55513-056-96	55513005696	1 SYRINGE in 1 CARTON (55513-056-96) / .05 mL in 1 SYRINGEMarketed from Oct 28, 2024

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Pavblu
Generic name (nonproprietary): aflibercept-ayyh
Active ingredients: Aflibercept — 2 mg/.05mL
Dosage form: Injection, Solution
Route: Intravitreal
Labeler: Amgen, Inc
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761298
Marketing start: Oct 28, 2024
Listing expires: Dec 31, 2027
Other FDA classes: Vascular Endothelial Growth Factor Inhibitors (Mechanism)
Identifiers: Product ID 55513-056_04e11a27-3d29-4776-bd2f-139a952423feSPL ID 04e11a27-3d29-4776-bd2f-139a952423feSPL set ID c61062f3-80ec-4a20-8c28-46e468592a06RxCUI 2696260, 2696267, 2696270, 2696274UNII 15C2VL427D
Pharmacologic class: Vascular Endothelial Growth Factor Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J0178 — Injection, aflibercept, 1 mg

Billing unit: 1 mg. Units on the claim = dose given ÷ 1 mg.

EYLEA HD and aflibercept biosimilars have their own HCPCS codes.

Administration

Intravitreal injection procedure (CPT 67028)

The intravitreal injection is reported as a separate procedure from the drug supplied.

How CPT relates to drug billing

NDC on a medical claim

N455513005601 followed by a unit qualifier and the quantity

Package 55513-0056-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 10, 2026.

Indications (excerpt from the label)

PAVBLU is indicated for the treatment of: PAVBLU is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1 ) Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2 ) Diabetic Macular Edema (DME) ( 1.3 ) Diabetic Retinopathy (DR) ( 1.4 ) 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761298

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761298
Product	Strength	Form · route	Labeler	Product NDC
Pavbluaflibercept-ayyh	Aflibercept 2 mg/.05mL	Injection, SolutionIntravitreal	Amgen, Inc	55513-065